Jorge Santos da Silva - 07 Jan 2026 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MLTX
Reported as of: 07 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jan 2026, 16:01:04 UTC
Prior SEC filing: 22 Dec 2025
Next SEC filing: 14 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Jorge Santos da Silva

Key filing fact

Jorge Santos da Silva filed Form 4 for MoonLake Immunotherapeutics (MLTX) on 09 Jan 2026.

Key facts

This page summarizes Jorge Santos da Silva's Form 4 filing for MoonLake Immunotherapeutics (MLTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jan 2026, 16:01.

Change

Previous filing in this sequence was filed on 22 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001920509 Primary reporting owner

Santos da Silva Jorge

Relationship: Chief Executive Officer, Director
Address: C/O MOONLAKE IMMUNOTHERAPEUTICS, DORFSTRASSE 29, ZUG, SWITZERLAND
Signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Jorge Santos da Silva
Signature date: 09 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MLTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +520,342
Change %
Price: $0.000000
Shares after: 520,342
Date: 07 Jan 2026
Ownership: Direct
Underlying class: Class A ordinary shares, par value $0.0001 per share
Underlying amount: 520,342
Exercise price: $11.29
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase a total of 520,342 of the Issuer's Class A ordinary shares, vesting in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.